Researchers discover underlying mechanisms of skin hardening syndromes
Researchers from Boston University School of Medicine (BUSM) have discovered new details about the underlying mechanisms of skin hardening syndromes. The team connected pharmacological properties of...
View ArticleNew development could increase flu vaccine supply
(Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed...
View ArticleNovartis fights patent rejection in Indian court
(AP) -- In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent...
View ArticleNovartis announces 2,000 job losses, profits up
Swiss pharmaceutical giant Novartis announced 2,000 job losses Tuesday, mostly in Switzerland and the United States, while reporting net profits of $3.53 billion (2.5 billion euros) for the third...
View ArticleFDA approves first drug for bone marrow disorder
The first drug to treat a rare disorder that causes red blood cells to build up inside bone marrow was cleared Wednesday by the Food and Drug Administration
View ArticleBig promise is seen in 2 new breast cancer drugs
(AP) -- Breast cancer experts are cheering what could be some of the biggest advances in more than a decade: two new medicines that significantly delay the time until women with very advanced cases get...
View ArticleStudy: Bone drug boosts breast cancer survival
(AP) -- Doctors were mostly hoping to prevent complications and relapses when they gave young women a medicine to keep their bones strong during breast cancer treatment. Seven years later, they found...
View ArticleSwiss pharma giant Novartis recalls drugs in US
Swiss pharmaceutical firm Novartis said Sunday it was recalling four different products sold over the counter in the United States over reports of a malfunction at one of its plants.
View ArticleFDA: Novartis recall may also affect painkillers
(AP) -- The Food and Drug Administration is warning patients about a potential mix-up between powerful prescription pain drugs and common over-the-counter medications like Excedrin and Gas-X made at a...
View ArticleFirst detailed data of risk of using Rasilez with certain blood...
Researchers at St. Michael's Hospital have published the first detailed figures showing the risk of using the prescription drug Rasilez in combination with certain other blood pressure-lowering...
View ArticleNovartis drug investigated after 11 deaths
A multiple sclerosis drug made by industry giant Novartis is under investigation after at least 11 patients taking the medicine died.
View ArticleDrug firms sign up to new tropical disease fight
Key players in the pharmaceutical industry pledged on Monday to donate 14 billion drug treatments as part of a new, global push to eradicate tropical diseases.
View ArticleVaccine discovered for hep C
(Medical Xpress) -- A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael...
View ArticleDelivery of child-friendly antimalarial hits the 100 million mark
One hundred million treatments of Coartem Dispersible (artemether-lumefantrine), an antimalarial developed especially for children with Plasmodium falciparum malaria, have been delivered by Novartis to...
View ArticleNovartis says EU approves expanded use of Glivec
Swiss pharmaceutical group Novartis said Monday the European Union will allow it to expand its use of the drug Glivec to treat certain rare forms of gastrointestinal cancer.
View ArticleResearch team finds compound that can spur cartilage growth
(Medical Xpress) -- A research team from drug maker Novartis has discovered a compound that spurs cartilage growth in mice. As they describe in their paper published in the journal Science, the team...
View ArticleNovartis tries to make UK hospitals use $1000 drug
(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).
View ArticleEU approves Novartis drug Signifor for Cushing's disease
European Union regulators have given Swiss pharmaceutical group Novartis a green light to market its drug Signifor as a treatment for Cushing's disease, the company said Wednesday.
View ArticleGreek crisis creates medicine shortages
Greece's highly uncertain future has forced businesses into a quasi hand-to-mouth existence, with one of the most alarming effects a shortage of medicines, including for the seriously ill.
View ArticleComputer model successfully predicts drug side effects
A new set of computer models has successfully predicted negative side effects in hundreds of current drugs, based on the similarity between their chemical structures and those molecules known to cause...
View ArticleNew drugs shore up Novartis in Q2
(AP) Swiss pharmaceutical company Novartis AG reported a net profit of $2.73 billion during the second quarter, as new drugs and acquisitions offset patent expirations, lower sales of generic...
View ArticleResearchers test new drug for patients with neuroendocrine tumors
A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230)...
View ArticleAfinitor disperz approved for rare pediatric cancer
(HealthDay)—The U.S. Food and Drug Administration has approved Afinitor Disperz (everolimus tablets for oral suspension), the first form of the anti-cancer drug Afinitor to be created especially for...
View ArticleEU approves Novartis-Incyte blood cancer drug
Novartis AG and Incyte Corp. said Tuesday that European Union regulators approved their blood cancer drug Jakavi.
View ArticleIndia's patent laws under pressure: The Lancet special report
In a special report in The Lancet, researchers from Queen Mary, University of London (UK) argue that pending cases against India's patent laws threaten public health and misinterpret international...
View ArticleNovartis chief sees sales dip until mid-2013
Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.
View ArticlePulmonary hypertension combination therapy may lead to greater disease burden
Patients with pulmonary arterial hypertension (PAH) receiving combination therapy with intravenous (IV) PGI2 may suffer from greater disease burden compared with those receiving monotherapy or...
View Article
